Novanta Inc. heads into its Q1 2026 results — scheduled for May 11 — with short sellers adding exposure at pace, the stock freshly bruised from a sharp weekly decline, and insider selling still fresh in the register.
The most striking development this week is the momentum in short positioning. Short interest has climbed to 11.6% of the free float — up 5.3% on the week and 14.9% over the past month. The build has been consistent and gradual, not a single spike. That persistence matters: from mid-March through April, estimated shorts rose from roughly 3.6 million shares to 4.15 million. The ORTEX short score is running at 71.9, near its highest reading of the recent period, which reflects the combination of rising shorts against limited squeeze pressure. Availability remains reasonably wide for a stock this shorted — cost to borrow is just 0.47% APR — meaning the borrow market is not putting a floor under short covering. There is no friction forcing out the bears.
Options tell a different story, and the contrast is worth noting. The put/call ratio has eased from its recent peak near 4.3 in late April to 3.47 — roughly 0.7 standard deviations below the 20-day mean of 3.69. That's modestly less defensive than it has been. The 52-week range on the PCR runs from 0.25 to 4.54, so the current reading is still well above the midpoint, but the direction of travel suggests options traders are not adding fresh downside protection into this price drop. Shorts are building; options hedgers are pulling back marginally. Those two signals are moving in opposite directions.
The stock closed Wednesday at $120.89, down 6.3% on the day and 9.2% on the week. That follows a 6.8% gain over the prior month, so the weekly selloff has erased most of that recovery. The Q4 2025 print in February showed the pattern: NOVT fell 6.4% the day results landed, then shed another 3% over the subsequent five days. Full-year 2025 sales came in at $980.6 million, up from $949.3 million a year earlier, but annual net income declined from $64 million to $54 million. The Q1 2026 result on May 11 will follow that February setup closely in terms of market positioning.
On the analyst side, coverage is thin — just two active buy ratings with no holds — and the latest action is stale enough to note with caution. Baird upgraded to Outperform in late March while lowering its target from $150 to $144. With the stock now at $120.89, that $144 target implies around 19% upside, though the target was set before the recent selldown. The EV/EBITDA multiple has compressed slightly over the past month to roughly 19.8x. The P/B has also contracted, falling 0.66 turns over 30 days to 6.0x. Valuation is tightening, but neither ratio looks distressed given Novanta's precision-technology profile.
Insider activity adds a cautious footnote. CEO Matthijs Glastra sold 6,500 shares at $130.05 on April 17 — a $845,000 transaction. CFO Robert Buckley sold nearly $1.2 million in shares across multiple tranches in mid-March. Net insider selling over the past 90 days totals roughly $4.6 million. These are modest relative to the float, but the timing — ahead of a scheduled earnings release — will be visible to any investor tracking the register. Among institutional holders, Allspring Global built a new position of 1.4 million shares in Q1, while Wasatch Advisors added 352,000 shares. Those are meaningful accumulations, providing a counterweight to the short build.
With Q1 results landing May 11, the setup concentrates attention on whether NOVT can break the pattern established in February. Shorts are at their highest level of the past six weeks, the stock has repriced lower, and insider sellers have been active. The next test is how those factors interact with the revenue and margin trajectory when numbers hit.
See the live data behind this article on ORTEX.
Open NOVT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
